NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

痙攣狀態治療的全球市場:2019年∼2023年

Global Spasticity Treatment Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 810918
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
痙攣狀態治療的全球市場:2019年∼2023年 Global Spasticity Treatment Market 2019-2023
出版日期: 2019年03月04日內容資訊: 英文 112 Pages
簡介

物理治療日益流行,成為帶動全球痙攣狀態治療市場成長的重要要素之一。因為副作用可抑制在最小限度,採用該物理治療治療的患者增加。根據物理治療的優點,獎勵各種醫院投資物理治療中心。同樣,在數個國家很多醫療當局及醫院,為了治療痙攣狀態等各種慢性疾病致力在醫院開啟物理治療中心。這導致提高患者的醫囑遵從性,預計在預測期間內帶動全球痙攣狀態治療市場成長。 Technavio的分析師預測,全球痙攣狀態治療市場至2023年,將以4%左右的年複合成長率成長。

本報告提供全球痙攣狀態治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 藥物療法
  • 物理治療
  • 市場機會:各類型

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • ALLERGAN
  • F. Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Pfizer Inc.
  • UCB SA

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR30912

About this market

The growing popularity of physical therapy is one of the key factors driving the growth of global spasticity treatment market. Patients are increasingly adopting this physical therapy treatment because it has minimal side effects. Several advantages of physiotherapy are encouraging various hospitals to invest in a physiotherapy center. Similarly, many healthcare authorities and hospitals of several countries are working on opening physical therapy centers in hospitals for the treatment of many chronic conditions such as spasticity. This will lead to increase patient adherence and is expected to drive the growth of the global spasticity treatment market during the forecast period. Technavio's analysts have predicted that the spasticity treatment market will register a CAGR of close to 4% by 2023.

Market Overview

Availability of advanced technologies for drug delivery

One of the growth drivers of the global spasticity treatment market is the availability of advanced technologies for drug delivery. The growing novel drug delivery systems help in delivering the drugs to the target site for improving treatment efficacy, which will drive the market growth during the forecast period.

A long time is taken to gain benefits in physical therapy

One of the challenges in the growth of the global spasticity treatment market is the long time taken to gain benefits in physical therapy. Several limitations such as long duration of physical therapy coupled with its high treatment costs and differences in service delivery create a negative impact on the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the spasticity treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are focusing on developing neurostimulation devices to treat spasticity in combination with medications available because sometimes physical therapies are compounded by the adverse side-effects. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Drug therapy - Market size and forecast 2018-2023
  • Physical therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • F. Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Pfizer Inc.
  • UCB S.A.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Drug therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Drug therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Physical therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Physical therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by type
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Market opportunity
  • Exhibit 40: Chronic conditions and spasticity: Overview
  • Exhibit 41: TBI-related hospitalizations by age group and injury mechanism in US 2006-2010
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Neurostimulation devices by companies
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: ALLERGAN - Vendor overview
  • Exhibit 50: ALLERGAN - Business segments
  • Exhibit 51: ALLERGAN - Organizational developments
  • Exhibit 52: ALLERGAN - Geographic focus
  • Exhibit 53: ALLERGAN - Key offerings
  • Exhibit 54: ALLERGAN - Key customers
  • Exhibit 55: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 56: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 57: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 58: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 59: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 60: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 61: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 62: Ipsen Pharma - Vendor overview
  • Exhibit 63: Ipsen Pharma - Business segments
  • Exhibit 64: Ipsen Pharma - Organizational developments
  • Exhibit 65: Ipsen Pharma - Geographic focus
  • Exhibit 66: Ipsen Pharma - Segment focus
  • Exhibit 67: Ipsen Pharma - Key offerings
  • Exhibit 68: Ipsen Pharma - Key customers
  • Exhibit 69: Pfizer Inc. - Vendor overview
  • Exhibit 70: Pfizer Inc. - Business segments
  • Exhibit 71: Pfizer Inc. - Organizational developments
  • Exhibit 72: Pfizer Inc. - Geographic focus
  • Exhibit 73: Pfizer Inc. - Segment focus
  • Exhibit 74: Pfizer Inc. - Key offerings
  • Exhibit 75: Pfizer Inc. - Key customers
  • Exhibit 76: UCB S.A. - Vendor overview
  • Exhibit 77: UCB S.A. - Business segments
  • Exhibit 78: UCB S.A. - Organizational developments
  • Exhibit 79: UCB S.A. - Geographic focus
  • Exhibit 80: UCB S.A. - Key offerings
  • Exhibit 81: UCB S.A. - Key customers
  • Exhibit 82: Validation techniques employed for market sizing